Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice

Journal of Hepatology

Volumn 55, Issue 2, 2011, Pages 359-368

  Wang, Jizhou ^a   Ma, Yong ^a   Jiang, Hongchi ^a   Zhu, Huaqiang ^a   Liu, Lianxin ^a   Sun, Bei ^a   Pan, Shangha ^a   Krissansen, Geoffrey W ^b   Sun, Xueying ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Hepatocellular carcinoma; Hypoxia inducible factor ; Nuclear factor B; von Hippel Lindau protein

Indexed keywords

ADENOVIRUS VECTOR; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG EFFICACY; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; LIVER CELL CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DOWN-REGULATION; DOXORUBICIN; GENE EXPRESSION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; RECOMBINANT PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79960445766     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.10.043     Document Type: Article

References (46)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009;21:CD001199.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology; 2010. www.aasld.org.
4. R.G. Gish, C. Porta, L. Lazar, P. Ruff, R. Feld, and A. Croitoru Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J Clin Oncol 25 2007 3069 3075
5. 2 sensing and cancer Nat Rev Cancer 8 2008 865 873
6. E.B. Rankin, and A.J. Giaccia The role of hypoxia-inducible factors in tumorigenesis Cell Death Differ 15 2008 678 685 (Pubitemid 351405072)
7. E. Poon, A.L. Harris, and M. Ashcroft Targeting the hypoxia-inducible factor (HIF) pathway in cancer Expert Rev Mol Med 11 2009 e26
8. M.S. Wiesener, J.S. Jürgensen, C. Rosenberger, C.K. Scholze, J.H. Hörstrup, and C. Warnecke Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs FASEB J 17 2003 271 273
9. G. Bangoura, Z.S. Liu, Q. Qian, C.Q. Jiang, G.F. Yang, and S. Jing Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma World J Gastroenterol 13 2007 3176 3182 (Pubitemid 47064579)
10. E.B. Rankin, J. Rha, T.L. Unger, C.H. Wu, H.P. Shutt, and R.S. Johnson Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice Oncogene 27 2008 5354 5358
11. J.K. Maranchie, J.R. Vasselli, J. Riss, J.S. Bonifacino, W.M. Linehan, and R.D. Klausner The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma Cancer Cell 1 2002 247 255 (Pubitemid 41039149)
12. Y. Lin, L. Bai, W. Chen, and S. Xu The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy Expert Opin Ther Targets 14 2010 45 55
13. M. Schön, B.G. Wienrich, S. Kneitz, H. Sennefelder, K. Amschler, and V. Vöhringer KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment J Natl Cancer Inst 100 2008 862 875 (Pubitemid 351881954)
14. Y.A. Wang, S.K. Johnson, B.L. Brown, and P.R. Dobson Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds Oncol Rep 21 2009 437 442
15. S. Maeda, H. Kamata, J.L. Luo, H. Leffert, and M. Karin IKK beta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis Cell 121 2005 977 990 (Pubitemid 40884391)
16. J. An, and M.B. Rettig Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity Mol Cell Biol 25 2005 7546 7556 (Pubitemid 41170117)
17. H. Yang, Y.A. Minamishima, Q. Yan, S. Schlisio, B.L. Ebert, and X. Zhang PVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kB agonist Card9 by CK2 Mol Cell 28 2007 15 27 (Pubitemid 47531976)
18. H. Qi, and M. Ohh The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway Cancer Res 63 2003 7076 7080 (Pubitemid 37413442)
19. J. An, M. Fisher, and M.B. Rettig VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism Oncogene 24 2005 1563 1570 (Pubitemid 40396086)
20. M. Baba, S. Hirai, H. Yamada-Okabe, K. Hamada, H. Tabuchi, and K. Kobayashi Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor Oncogene 22 2003 2728 2738 (Pubitemid 36609588)
21. S. Koochekpour, M. Jeffers, P.H. Wang, C. Gong, G.A. Taylor, and L.M. Roessler The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells Mol Cell Biol 19 1999 5902 5912 (Pubitemid 29399295)
22. P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E.J. Oakeley, and W. Krek Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL Nature 425 2003 307 311 (Pubitemid 37158407)
23. A.M. Roberts, I.R. Watson, A.J. Evans, D.A. Foster, M.S. Irwin, and M. Ohh Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells Cancer Res 69 2009 9056 9064
24. I.J. Frew, C.R. Thoma, S. Georgiev, A. Minola, M. Hitz, and M. Montani PVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation EMBO J 27 2008 1747 1757
25. X. Sun, J.R. Kanwar, E. Leung, M. Vale, and G.W. Krissansen Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha Gene Ther 10 2003 2081 2089 (Pubitemid 37483650)
26. X. Sun, M. Liu, Y. Wei, F. Liu, X. Zhi, and R. Xu Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas Cancer Gene Ther 13 2006 428 435
27. F. Liu, P. Wang, X. Jiang, G. Tan, H. Qiao, and H. Jiang Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma Cancer Sci 99 2008 2055 2061
28. M. Johnson, S. Huyn, J. Burton, M. Sato, and L. Wu Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction Hum Gene Ther 17 2006 1262 1269 (Pubitemid 44975142)
29. R. Kong, B. Sun, H. Jiang, S. Pan, H. Chen, and S. Wang Downregulation of nuclear factor-κB P65 subunit by small interfering RNA synergizes with gemcitabine to treat pancreatic cancer Cancer Lett 291 2010 90 98
30. Y.X. Chen, K. Man, G.S. Ling, Y. Chen, B.S. Sun, and Q. Cheng A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10 J Immunol 179 2007 6009 6015
31. Z. Mai, G.L. Blackburn, and J.R. Zhou Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice Carcinogenesis 28 2007 1217 1223 (Pubitemid 47062680)
32. D. Wang, Z. Wang, B. Tian, X. Li, S. Li, and Y. Tian Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs Int J Urol 15 2008 435 441 (Pubitemid 351623895)
33. X. Sun, H. Jiang, X. Jiang, H. Tan, Q. Meng, and B. Sun Downregulating hypoxia-inducible factor 1 augments transcatheter arterial embolization to treat hepatocellular carcinomas in rats Human Gene Ther 20 2009 314 324
34. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 2001 987 989 (Pubitemid 32937367)
35. B. Sun, and M. Karin NF-kappaB signaling, liver disease and hepatoprotective agents Oncogene 27 2008 6228 6244
36. J.M. Wu, H. Sheng, R. Saxena, N.J. Skill, P. Bhat-Nakshatri, and M. Yu NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy Cancer Lett 278 2009 145 155
37. K.J. Campbell, S. Rocha, and N.D. Perkins Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B Mol Cell 13 2004 853 865 (Pubitemid 38438480)
38. K. Ashikawa, S. Shishodia, I. Fokt, W. Priebe, and B.B. Aggarwal Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues Biochem Pharmacol 67 2004 353 364 (Pubitemid 38112765)
39. M. Kim, Y. Katayose, Q. Li, A.N. Rakkar, Z. Li, and S.G. Hwang Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 Biochem Biophys Res Commun 253 1998 672 677 (Pubitemid 29039201)
40. M.A. Kern, A.M. Haugg, A.F. Koch, T. Schilling, K. Breuhahn, and H. Walczak Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma Cancer Res 66 2006 7059 7066 (Pubitemid 44197682)
41. M.K. Jones, I.L. Szabó, H. Kawanaka, S.S. Husain, and A.S. Tarnawski von Hippel-Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis FASEB J 16 2002 264 266
42. Y.Q. Wang, J.M. Luk, K. Ikeda, K. Man, A.C. Chu, and K. Kaneda Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells Biochem Biophys Res Commun 317 2004 358 362 (Pubitemid 38452490)
43. J. Rius, M. Guma, C. Schachtrup, K. Akassoglou, A.S. Zinkernagel, and V. Nizet NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha Nature 453 2008 807 811 (Pubitemid 351793778)
44. K. Lee, D.Z. Qian, S. Rey, H. Wei, J.O. Liu, and G.L. Semenza Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells Proc Natl Acad Sci USA 106 2009 2353 2358
45. W.C. Ho, K.M. Dickson, and P.A. Barker Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells Cancer Res 65 2005 4273 4281 (Pubitemid 40775666)
46. J.M. Llovet, M.I. Real, X. Montana, R. Planas, S. Coll, and J. Aponte Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma, a randomised controlled trial Lancet 359 2003 1734 1739